TRIPS协议与公共健康议题谈判的成果与展望—评《多哈宣言第六段的执行决议》(下)/严海(26)
148. 参见邓常春《近五年来印度〈专利法〉的修改对其制药业的影响》，载《南亚研究季刊》，2005年第2期，第32页以下。
149. 参见印度1970年专利法（1999年修订），第三部分，(d), (e)； 印度2004年《专利（修订）条例》第三段。
150. An Act to Amend the Patent Act and the Food and Drug Act, Bill C-56, 51-52 Elizabeth II (200202003), available at http://www.parl.gc.ca/37/2/parlbus/chambus/house/bills/government/c-56/c-56_1/90247bE.html. (Last Visited on Nov. 8, 2005).
151. Patent Act, R.S.C. 1985, ch. P-4.
152. Food & Drugs Act, R.S.C. 1985, c. F-27.
153. 前引150，Patent Act, 21.04(1).
154. 前引150，Patent Act, 21.04(1).
155. 前引150，Patent Act, 21.08.
156. 前引150，Patent Act, 21.17(1).
157. 前引150，Patent Act, 21.17(5).
158. 关于加拿大立法的详细情况，可以参考Mark D. Penner, Prakash Narayanan, Amendments to the Canadian Patent Act to Address Drug Access: Is Help on the Way? 60 Food Drug L.J. 459 (2005).
159. See Consultation—Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health (Excerpts), at http://www.dep.no/ud/engelsk/p2500832/p30003923/032121-290003/index-dokOOO-b-n-a.html (last visited Aug. 8, 2005).
总共33页
[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 26
[27] [28] [29] [30] [31] [32] [33] 上一页 下一页